Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Giant cell arteritis

E Nordborg1, C Nordborg, B E Malmvall

  • 1Division of Rheumatology, Sahlgrenska University Hospital, Göteborg, Sweden.

Rheumatic Diseases Clinics of North America
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormones, body composition and cardiovascular risk.

Asia Pacific journal of clinical nutrition·2014
Same author

The effects of growth hormone on body composition.

Asia Pacific journal of clinical nutrition·2014
Same author

Heat production, nerve function, and morphology following nerve close dissection with surgical instruments.

World journal of surgery·2012
Same author

Update of the original HDLS kindred: divergent clinical courses.

Acta neurologica Scandinavica·2011
Same author

Acute aortic dissection in a patient with extremely low body mass index due to anorexia nervosa.

The Journal of cardiovascular surgery·2011
Same author

Late cerebral graft versus host reaction in a bone marrow transplanted girl with Hurler (MPS I) disease.

Neuropediatrics·2009

Giant cell arteritis (GCA) is increasingly recognized as a significant cause of illness in older adults, though its origins remain unclear. Glucocorticosteroids are the primary treatment, while nonsteroidal anti-inflammatory drugs are not recommended for GCA complications.

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Vascular Inflammation

Background:

  • Giant cell arteritis (GCA) incidence has risen significantly in elderly populations over the past 50 years.
  • GCA is now a major contributor to morbidity in older individuals.
  • The underlying causes and pathogenesis of GCA are not well understood.

Purpose of the Study:

  • To summarize the current understanding of Giant Cell Arteritis.
  • To highlight the established treatment protocols for GCA.
  • To clarify the role of different anti-inflammatory drug classes in managing GCA.

Main Methods:

  • Literature review of GCA epidemiology and treatment.
  • Analysis of clinical guidelines for GCA management.
  • Evaluation of the efficacy of anti-inflammatory drugs in GCA.

Related Experiment Videos

Main Results:

  • Giant cell arteritis is a growing concern for elderly health.
  • Glucocorticosteroids are the established first-line therapy for all forms of GCA.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) have demonstrated no benefit for vascular complications in GCA.

Conclusions:

  • Giant cell arteritis requires continued research into its etiology and pathogenesis.
  • Glucocorticosteroids remain the cornerstone of GCA treatment.
  • NSAIDs should not be relied upon for managing GCA or its vascular sequelae.